Inhibition of matrix metalloproteinase-9 activity by lisinopril after myocardial infarction in hamsters.
We measured angiotensin-converting enzyme and matrix metalloproteinase-9 activities after myocardial infarction in hamsters and compared the effects of an angiotensin-converting enzyme inhibitor lisinopril with those of an angiotensin receptor blocker candesartan cilexetil after myocardial infarction. Angiotensin-converting enzyme activity was significantly increased 3 and 7 days, but not 1 day after myocardial infarction. Matrix metalloproteinase-9 activity was significantly increased 1 day after myocardial infarction. Lisinopril significantly inhibited both angiotensin-converting enzyme and matrix metalloproteinase-9 activities, but candesartan cilexetil did not. Angiotensin-converting enzyme inhibitors might directly inhibit matrix metalloproteinase-9 activity.
Takai
Shinji
S
Department of Pharmacology, Osaka Medical College, Takatsuki City, Osaka 589-8686, Japan. pha010@art.osaka-med.ac.jp
Yamamoto
Daisuke
D
Jin
Denan
D
Inagaki
Sachiko
S
Yoshikawa
Katsuhiro
K
Tanaka
Kazuhiko
K
Miyazaki
Mizuo
M
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D006224:Cricetinae; D006352:Heart Ventricles / Q000201:enzymology; D017706:Lisinopril / Q000494:pharmacology*; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D061965:Matrix Metalloproteinase Inhibitors; D009203:Myocardial Infarction / Q000201:enzymology*; D007703:Peptidyl-Dipeptidase A / Q000378:metabolism
D000806:Angiotensin-Converting Enzyme Inhibitors; D061965:Matrix Metalloproteinase Inhibitors; D017706:Lisinopril; D007703:Peptidyl-Dipeptidase A; D020780:Matrix Metalloproteinase 9